Klin Farmakol Farm. 2013;27(2):92-94

Papulopustular exanthema as an adverse effect of cetuximab

Kateřina Kučerová1, Jaroslav Urbánek2
1 Fakulta zdravotnických věd, Univerzita Palackého Olomouc
2 Klinika chorob kožních a pohlavních, Fakultní nemocnice Olomouc

The monoclonal antibody cetuximab, an inhibitor of epidermal growth factor receptor (EGFR), has been effectively used to treat various

types of cancer. However, these agents frequently cause skin toxicity, which is due to the expression of the EGFR in the skin. This

adverse effect impairs the quality of life of cancer patients and, in severe cases, requires dose reduction, or rarely, even discontinuation

of treatment. Therefore, timely initiation of anticancer therapy is important.

Keywords: cetuximab, inhibitor of epidermal growth factor, EGFR, skin toxicity, acneiform rash

Published: July 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kučerová K, Urbánek J. Papulopustular exanthema as an adverse effect of cetuximab. Klin Farmakol Farm. 2013;27(2):92-94.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Tomková H, Pospíšková M, Zábojníková M, et al. Phytomenadione pre-treatment in EGFR inhibitor-induced folliculitis: Journal of the European Academy of Dermatology and Venereology. JEADV 2011? 1-6. Go to original source...
    2. Li T, Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Targ Oncol 2009? 4: 107-118. Go to original source... Go to PubMed...
    3. Lacouture Mario E, Anadkat Milan J, Bensadoun René-Jean, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 2011; 19: 1079-1095. Go to original source... Go to PubMed...
    4. Česká onkologická společnost ČLS JEP. Zásady cytostatické léčby maligních onkologických onemocnění. Česká onkologická společnost 2010? 10: 145-146.
    5. Giovannini M, Gregorc V, Belli C, et al. Clinical Significance of Skin Toxicity due to EGFR-Targeted Therapies. Journal of Oncology 2009: 1-3. Go to original source... Go to PubMed...
    6. Melichar B. Cetuximab. Remedia [online] 2007? 1/2007. Dostupné na WWW: http://www.remedia.cz/Archiv-rocniku/Rocnik-2007/1-2007/Cetuximab/e-9p-9V-hg.magarticle.aspx.
    7. Baas JM, Krens LL, Guchelaar HJ, et al. Recommendations on management of EGFR inhibitor-induced skin toxicity: A systematic review. Cancer Treatment Reviews 2012? 38: 505-514. Go to original source... Go to PubMed...
    8. Holubec L, Říčař J, Pizinger K, et al. Léčba kožní toxicity u nemocné s metastazujícím kolorektálním karcinomem léčené cetuximabem - klinická kazuistika. Onkologie 2012; 6(5): 279-280.
    9. Bianchini D, Jayanth A, Chua YJ, et al. Epidermal Growth Factor Receptor Inhibitor - Related Skin Toxicity: Mechanisms, Treatment, and its Potential Role as a Predictive Marker. Clinical Colorectal cancer 2008? 7(1): 33-43. Go to original source... Go to PubMed...
    10. Pinto C, Barone BA, Girolomoni G, et al. Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy. The Oncologist 2011; 16: 228-238. Go to original source... Go to PubMed...
    11. Wang K, Li W, Huang T, Li R, Wang, et al. Characterizing breast cancer xenograft epidermal growth factor receptor expression by using near-infrared optical imaging. Acta Radiol 2009; 50: 1095-1103. Go to original source... Go to PubMed...
    12. Fínek J. Cetuximab (Erbitux(R)) v léčbě kolorektálního karcinomu. Zdravotnické noviny 2007? 3/2007. Dostupné na WWW: http://zdravi.e15.cz/clanek/priloha-lekarske-listy/cetuximab-erbitux-v-lecbe-kolorektalniho-karcinomu-289931.
    13. Česká onkologická společnost ČLS JEP. 31. Doporučení pro léčbu kožních změn v důsledku terapie inhibitory EGFR: Modrá kniha české onkologické společnosti [online] 2013? 16/2013. Dostupné na WWW: http://www.linkos.cz/informace-pro-praxi/modra-kniha/31-doporuceni-pro-lecbu-koznich-zmen-v-dusledku-terapie-inhibitory-egfr/.

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.